We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site
Abveris on important lessons learned through using the Beacon system for antibody discovery.
Thermo Fisher Scientific on developing a faster, more efficient, and regulatory ready cell line and cell culture.
Samsung Biologics on how to expedite development timeline and obtain IND clearance and starting phase 1 study faster.
Thermo Fisher Scientific on how to get more molecules to the clinic faster.
Medical College of Wisconsin on how to determine the phenotypic and functional characteristics of cells in real time, isolate specific cells of interest, and link the genomic profiles of these same cells using downstream assays.
Abveris, Genovac, and Berkeley Lights on the evolving landscape of antibody therapeutics, the technologies they have turned to to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
Genovac on how to find 10 times more lead candidates than hybridoma in just days.
Genovac and Berkeley Lights on how to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Nobel Laureate, Dr. James Rothman, Amgen, Catalent-Biologics, and University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.
Vanderbilt University Medical Center on how to rapidly discover hundres of unique antibodies against SARS-CoV-2.
Children’s Hospital of Philadelphia shares insight into why children’s T cells help CAR-T cells succeed and how to develop more efficacious therapies.
Abveris on how to accelerate the development of next-generation antibody therapeutics.